OTCMKTS:RCPIQ - Rock Creek Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.0005 0.00 (0.00 %) (As of 05/26/2019 04:00 PM ET)Previous Close$0.0005Today's Range$0.0005 - $0.000552-Week Range$0.0003 - $0.0019Volume46,044 shsAverage Volume185,663 shsMarket Capitalization$85,225.00P/E RatioN/ADividend YieldN/ABeta2.65 ProfileChartEarningsFinancialsInsider TradesHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Rock Creek Pharmaceuticals, Inc., a pharmaceutical development company, focuses on the discovery, development, and commercialization of therapies for chronic inflammatory disease and neurologic disorders. Its lead compound is Anatabine citrate, a small molecule, cholinergic agonist, which exhibits anti-inflammatory pharmacological characteristics, with a mechanism of action distinct from other anti-inflammatory drugs available, such as biologics, steroids, and non-steroidal anti-inflammatories. The company was formerly known as Star Scientific, Inc. and changed its name to Rock Creek Pharmaceuticals, Inc. in June 2014. Rock Creek Pharmaceuticals, Inc. is headquartered in Sarasota, Florida. On September 27, 2016, Rock Creek Pharmaceuticals, Inc., along with its affiliates, filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the District of Delaware. Receive RCPIQ News and Ratings via Email Sign-up to receive the latest news and ratings for RCPIQ and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Medicinals & botanicals Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:RCPIQ Previous SymbolNASDAQ:RCPI CUSIPN/A CIK776008 Webhttp://www.rockcreekpharmaceuticals.com/ Phone844-727-0727Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees5 Outstanding Shares170,450,000Market Cap$85,225.00 Next Earnings DateN/A OptionableNot Optionable Rock Creek Pharmaceuticals (OTCMKTS:RCPIQ) Frequently Asked Questions What is Rock Creek Pharmaceuticals' stock symbol? Rock Creek Pharmaceuticals trades on the OTCMKTS under the ticker symbol "RCPIQ." Has Rock Creek Pharmaceuticals been receiving favorable news coverage? Media headlines about RCPIQ stock have been trending somewhat negative on Sunday, InfoTrie Sentiment reports. The research group scores the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Rock Creek Pharmaceuticals earned a news sentiment score of -1.8 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 9.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the near term. Who are some of Rock Creek Pharmaceuticals' key competitors? Some companies that are related to Rock Creek Pharmaceuticals include Actelion (ALIOF), Canopy Growth (CGC), Aurora Cannabis (ACB), Cronos Group (CRON), Tilray (TLRY), USANA Health Sciences (USNA), CV Sciences (CVSI), Chromadex (CDXC), Canopy Rivers (RIV), Foamix Pharmaceuticals (FOMX), Mediwound (MDWD), Natural Alternatives International (NAII), Mannatech (MTEX), China Jo-Jo Drugstores (CJJD) and Cyanotech (CYAN). What other stocks do shareholders of Rock Creek Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Rock Creek Pharmaceuticals investors own include SLS International (SLS), Capstone Turbine (CPST), Keryx Biopharmaceuticals (KERX), Plug Power (PLUG), Acer Therapeutics (ACER), Catalyst Pharmaceuticals (CPRX), Curis (CRIS), DryShips (DRYS), GenVec (GNVC) and Microbot Medical (MBOT). Who are Rock Creek Pharmaceuticals' key executives? Rock Creek Pharmaceuticals' management team includes the folowing people: Dr. Michael John Mullan MBBS (M.D., ), Ph.D., Chairman, Chief Exec. Officer and Pres (Age 62)Dr. Curtis Wright IV, Sr. VP and Medical & Clinical Director (Age 70) How do I buy shares of Rock Creek Pharmaceuticals? Shares of RCPIQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Rock Creek Pharmaceuticals' stock price today? One share of RCPIQ stock can currently be purchased for approximately $0.0005. How big of a company is Rock Creek Pharmaceuticals? Rock Creek Pharmaceuticals has a market capitalization of $85,225.00. Rock Creek Pharmaceuticals employs 5 workers across the globe. What is Rock Creek Pharmaceuticals' official website? The official website for Rock Creek Pharmaceuticals is http://www.rockcreekpharmaceuticals.com/. How can I contact Rock Creek Pharmaceuticals? Rock Creek Pharmaceuticals' mailing address is 2040 WHITFIELD AVE. SUITE 300, SARASOTA FL, 34243. The company can be reached via phone at 844-727-0727 or via email at [email protected] MarketBeat Community Rating for Rock Creek Pharmaceuticals (OTCMKTS RCPIQ)Community Ranking: 2.2 out of 5 ( )Outperform Votes: 60 (Vote Outperform)Underperform Votes: 74 (Vote Underperform)Total Votes: 134MarketBeat's community ratings are surveys of what our community members think about Rock Creek Pharmaceuticals and other stocks. Vote "Outperform" if you believe RCPIQ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RCPIQ will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/26/2019 by MarketBeat.com StaffFeatured Article: Consumer Price Index (CPI) Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.